Introduction
Immune checkpoint blockade (ICB) has reshaped the treatment landscape of gastric cancer (GC), yet objective response rates to ICB monotherapy remain approximately 10–15% in unselected advanced GC, largely attributable to an immunosuppressive tumor microenvironment (TME). Tumor-derived extracellular vesicles (TEVs) have emerged as pivotal couriers of intercellular crosstalk within the TME, capable of remodeling infiltrating immune populations to foster an immunosuppressive niche. Yet the specific cargoes through which TEVs orchestrate immune evasion and drive ICB resistance in GC remain largely undefined.
Aims & Methods
We sought to identify functional TEV cargoes and their cellular targets that underpin ICB resistance in GC. Integrative analyses of TCGA-STAD, public ICB-treated GC cohorts, and GC single-cell transcriptomes were performed to link the EV/ESCRT program to clinical response, cellular origin, and immune cross-talk. Comparative proteomic profiling of TEVs from gastric cancer cell lines (SNU-719, MKN-45) versus normal gastric epithelium (GES-1) was performed, and candidate cargoes were nominated by intersection analysis. Spatial relationships between the nominated cargo DDX3X, tumor-associated neutrophils, and CD8⁺ T cells were validated in a GC patient cohort by multiplex immunofluorescence. Cargo transfer and downstream mechanisms were dissected in human differentiated HL-60 (dHL-60) neutrophils and murine tumor-infiltrating neutrophils using EV co-culture, flow cytometry, RIP-seq, and CD8⁺ T-cell suppression assays. Therapeutic efficacy was evaluated in orthotopic YTN16 syngeneic gastric cancer models treated with the DDX3X small-molecule inhibitor RK-33 in combination with anti–PD-1 antibody.
Results
EV/ESCRT signature scores were elevated in ICB non-responders and, in TCGA-STAD, selectively correlated with MDSC-like and PMN-MDSC-like infiltration and T-cell exhaustion, but not with M2 macrophage or NK cytotoxic signatures—implicating TEV biogenesis in neutrophil-skewed immune evasion. Intersectional TEV proteomics nominated DDX3X as a top GC-enriched cargo. Single-cell analysis localized DDX3X expression predominantly to malignant epithelial cells and identified the tumor cell–neutrophil axis as a prominent communication module within the GC microenvironment. Consistent with these findings, multiplex immunofluorescence of patient tumors showed that DDX3X-high regions harbored increased infiltration of tumor-associated neutrophils (TANs) alongside reduced CD8⁺ T-cell density. Mechanistically, TEV-delivered DDX3X was internalized by neutrophils and reprogrammed them toward an immunosuppressive phenotype characterized by ARG1 upregulation, which in turn blunted CD8⁺ T-cell proliferation and effector cytokine production. In vivo, RK-33 synergized with anti–PD-1 blockade, markedly reducing tumor burden and restoring intratumoral CD8⁺ T-cell infiltration and effector function compared with either monotherapy.
Conclusion
We identify exosomal DDX3X as a previously unrecognized driver of tumor–neutrophil crosstalk and ICB resistance in gastric cancer. Co-targeting the TEV–DDX3X–neutrophil axis represents a rational combinatorial strategy to overcome resistance and broaden clinical benefit from immune checkpoint blockade in GC.